“This isn’t just a platform – it’s about patients. Capsida’s approach unlocks the potential to treat both rare and common diseases across all ages.”

Swati Tole, CMO

Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders.  We blend innovation with execution in the pursuit to improve patient lives.

Science & Innovation


Capsid Engineering, Cargo Optimization, Translational Biology, Process Development and Manufacturing, and Clinical Development – All Under One Roof

Capsida Biotherapeutics is the only fully integrated gene therapy platform company that through intravenous (IV) delivery of a single, engineered capsid can target individual or multiple organs simultaneously while limiting exposure to non-targeted organs.

Built through a combination of in-house R&D and industry partnerships, our therapeutic approaches – including gene replacement and gene editing – are designed to bring therapies to patients with both monogenic and polygenic diseases.


Capsid Engineering

At Capsida, the scale at which we can engineer and screen capsids is unrivaled. Using our automated, high-throughput biological screening method, our scientists assess large, diverse engineered capsid libraries to quickly identify optimal capsids to target tissues and cells in diseased organs.


Discovery and Preclinical

To quickly advance our mission of providing meaningful therapeutic opportunities for patients with unmet medical need, Capsida optimizes cargo and evolves preclinical disease proof-of-concept in parallel with capsid engineering. Our engineered capsids can be optimized to deliver a broad range of cargos including gene replacement, gene editing, gene silencing and vectorized antibodies, among others.


Manufacturing Operations

At Capsida, we are singularly focused on rapidly getting our high-quality, life-changing therapies to patients who are suffering from debilitating diseases. We have built capabilities to perform everything in-house, eliminating the need for contract development and manufacturing organizations (CDMOs). We streamline the entire process, from selecting our therapies for manufacturability through scalable process development. Ultimately, this helps us get therapeutics to patients sooner.


Clinical Development

Capsida’s approach unlocks the potential to treat both rare and common diseases across all ages. First and foremost, we approach patients holistically, working closely with advocacy groups, patients, and caregivers to ensure we are meeting their needs.



Capsida’s innovation and intellectual property can be broadly applied to all therapeutic areas. We’re starting in the Central Nervous System (CNS) because of the significant prevalence and unmet need in CNS disorders.


Capsida’s founding technology originated in the lab of Caltech’s Viviana Gradinaru, Ph.D., Professor of Neurosciences and Biological Engineering at the Tianqiao and Chrissy Chen Institute of Neuroscience. Founded in 2019, Capsida is financed by Versant Ventures and Westlake Village BioPartners and has entered into a strategic partnership with AbbVie for treating neurodegenerative disease.

Our leaders have decades of experience in the biopharmaceutical industry and expertise in AAV biology and biologics manufacturing.


“We welcome the opportunity to collaborate with innovators who share our determination to develop transformative gene therapies for patients.”

Bethany Mancilla, Chief Business Officer

Capsida’s approach unlocks the potential to treat both rare and common diseases across all ages. Our goal is to apply the strength of our targeted gene therapy platform to develop a new generation of transformative therapies.

Learn More



Capsida is a rapidly growing company based in the heart of the Greater Los Angeles biotech hub. We’re looking for passionate, dedicated colleagues to join us!

Learn More

News & Events


Capsida Biotherapeutics Announces Appointment of Julie Hakim as Chief Financial Officer

Hakim brings more than 25 years’ experience leading finance and exponential growth at both large and small companies THOUSAND OAKS, Calif., January 18, 2023 —…

Capsida Biotherapeutics Announces Strategic Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Develop Non-Invasive Gene Therapies for CNS Diseases

THOUSAND OAKS, Calif.  January 4, 2023 – Capsida Biotherapeutics Inc. (“Capsida”) today announced a multi-year strategic collaboration with Prevail…